Business
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
Brightplex technology, acquired from HalioDx, is designed to help drug developers understand and leverage the tumor micro-environment SOUTH SAN FRANCISCO,
About this update from Veracyte, Inc.
[{"type":"text","content":"\nBrightplex technology, acquired from HalioDx, is designed to help drug developers understand and leverage the tumor micro-environment\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting the company’s immuno-oncology offerings for biopharmaceutical researchers will be presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place in Washington, DC and virtually, November 10-14, 2021.\n\n“It is exciting to have the opportunity to present new data on our Brightplex assays and be able to provide to clinical researchers innovative solutions designed to help them better understand the mechanism of action for therapeutics,” said Corinne Danan, Veracyte’s general manager, Biopharma. “This is especially important in the immuno-oncology field where the micro-environment of the tumor plays a key role in cancer progression and response to therapy.”\n\nVeracyte acquired the novel Brightplex technology – which combines information from multiplex immunohistochemistry (IHC) and advanced digital pathology analysis to provide a comprehensive picture of the tumor micro-environment – through its acquisition of HalioDx in August 2021.\n\nThe following posters will be presented at the SITC meeting:\n\nPoster Title: “Assessment of the spatial distribution of B cells subpopulations in the tumor microenvironment and tertiary lymphoid structures by Brightplex®, a sequential chromogenic multiplex assay”\nAbstract number: 57\nSession Date/Time: Nov. 12, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)\n\nPoster Title: “Assessment of the spatial distribution of CD4+ T cells subpopulations in the tumor microenvironment by Brightplex®, a sequential chromogenic multiplex assay”\nAbstract number: 41\nSession Date/Time: Nov. 12, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)\n\nPoster Title: “Spatial distribution of infiltrating T lymphocytes with Immunoscore® CR T Cells Exhaustion test helps stratification of NSCLC patients treated with PD1/L1 inhibitors in the PIONeeR project”\nAbstract number: 460\nSession Date/Time: Nov. 13, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)\n\nAbout Veracyte\n\nVeracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by ...